Incyte (INCY) Tops Q4 EPS by 18c, Revenues Beat

Incyte (NASDAQ: INCY) reported Q4 EPS of $0.93, $0.18 better than the analyst estimate of $0.75. Revenue for the quarter came in at $789.51 million versus the consensus estimate of $662.94 million.

“Our team achieved many important accomplishments in the past year. Revenue growth was strong, driven by demand for Jakafi® (ruxolitinib), and the launches of Monjuvi® (tafasitamab-cxix) and Pemazyre® (pemigatinib) continue to gain momentum. During 2020, we also announced positive results across multiple late-stage programs, including the pivotal trials of ruxolitinib in chronic GVHD, ruxolitinib cream in atopic dermatitis, parsaclisib in NHL, and retifanlimab in SCAC,” stated Hervé Hoppenot, Chief Executive Officer, Incyte. “During 2021, we expect regulatory decisions on seven applications seeking approval, including four in the U.S, two in Europe and one in Japan, and we are working towards the potential U.S. launch of ruxolitinib cream, which we expect to be approved by the FDA in the middle of the year.”

For earnings history and earnings-related data on Incyte (INCY) click here.

You May Also Be Interested In

• Philip Morris (PM) beats Q1 earnings, revenue estimates; issues upbeat guidance
• NextEra Energy (NEE) Tops Q1 EPS by 16c, provides guidance
• Dime Community Bancshares (DCOM) Tops Q1 EPS by 1c